Patents Assigned to THE PROVOST, FELLOWS, FOUNDATION SCHOLARS AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEEN ELIZABETH NEAR DUBLIN
Abstract: The present invention relates generally to the field of immunomodulation. Taught herein is an agent for inhibiting immunostimulation mediated by a Toll-like receptor useful in the treatment of viral and microbial pathogenesis, diseases involving elements of autoimmunity and inflammation as well as cancer. The agent antagonizes disulfide bond formation between C98 and C475 of Toll-like receptor 7 (TLR7) thereby preventing TLR7 activation. Pharmaceutical compositions are also enabled herein.
Type:
Grant
Filed:
June 29, 2018
Date of Patent:
May 3, 2022
Assignees:
ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY, UNIVERSITY OF SOUTH AUSTRALIA, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEEN ELIZABETH NEAR DUBLIN, MONASH UNIVERSITY
Inventors:
Stavros Selemidis, Doug A. Brooks, John O'Leary